DT
HealthMore in Health→
Experimental ovarian cancer drug posts early signs of benefit in phase 1 trial
Key Takeaways
- QLS5132 is an investigational ADC targeting CLDN6 in advanced platinum-resistant ovarian cancer.
- In a 28-patient phase 1 study, adverse events were common but no treatment-related event caused discontinuation or death.
- Researchers say the trial showed an early signal of clinical benefit in a heavily pretreated population.
DE
DT Editorial Team··via medicalxpress.com